Cidara Therapeutics, Inc. (CDTX): Price and Financial Metrics


Cidara Therapeutics, Inc. (CDTX): $1.56

-0.03 (-1.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CDTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

CDTX POWR Grades


  • Sentiment is the dimension where CDTX ranks best; there it ranks ahead of 98.93% of US stocks.
  • CDTX's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • CDTX's current lowest rank is in the Momentum metric (where it is better than 4.48% of US stocks).

CDTX Stock Summary

  • Of note is the ratio of Cidara Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 8.29% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Cidara Therapeutics Inc is higher than it is for about merely 10.17% of US stocks.
  • With a year-over-year growth in debt of -50.06%, Cidara Therapeutics Inc's debt growth rate surpasses merely 9.49% of about US stocks.
  • Stocks that are quantitatively similar to CDTX, based on their financial statements, market capitalization, and price volatility, are ORGS, AUTL, XCUR, VBLT, and CANF.
  • CDTX's SEC filings can be seen here. And to visit Cidara Therapeutics Inc's official web site, go to www.cidara.com.

CDTX Valuation Summary

  • In comparison to the median Healthcare stock, CDTX's EV/EBIT ratio is 104.78% lower, now standing at -1.4.
  • CDTX's price/earnings ratio has moved up 14.8 over the prior 78 months.
  • CDTX's price/earnings ratio has moved up 14.8 over the prior 78 months.

Below are key valuation metrics over time for CDTX.

Stock Date P/S P/B P/E EV/EBIT
CDTX 2021-08-31 2.8 7.2 -2.3 -1.4
CDTX 2021-08-30 2.6 6.8 -2.2 -1.3
CDTX 2021-08-27 2.5 6.6 -2.1 -1.2
CDTX 2021-08-26 2.5 6.4 -2.1 -1.2
CDTX 2021-08-25 2.6 6.8 -2.2 -1.3
CDTX 2021-08-24 2.5 6.5 -2.1 -1.2

CDTX Growth Metrics

  • Its year over year revenue growth rate is now at -49.05%.
  • The 3 year cash and equivalents growth rate now stands at 11.03%.
  • Its 5 year net income to common stockholders growth rate is now at -31.32%.
Over the past 67 months, CDTX's revenue has gone up $41,416,000.

The table below shows CDTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 41.416 -23.564 -48.739
2021-03-31 11.945 -41.076 -75.864
2020-12-31 12.067 -54.411 -74.873
2020-09-30 10.153 -58.48 -67.262
2020-06-30 26.837 -27.778 -47.035
2020-03-31 23.445 -26.514 -42.276

CDTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDTX has a Quality Grade of B, ranking ahead of 87.74% of graded US stocks.
  • CDTX's asset turnover comes in at 0.684 -- ranking 42nd of 681 Pharmaceutical Products stocks.
  • VNRX, PBH, and KALA are the stocks whose asset turnover ratios are most correlated with CDTX.

The table below shows CDTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.684 1 2.529
2021-03-31 0.190 1 4.489
2020-12-31 0.171 1 6.027
2020-09-30 0.140 1 5.823
2020-06-30 0.348 1 4.233
2020-03-31 0.327 1 5.374

CDTX Price Target

For more insight on analysts targets of CDTX, see our CDTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.17 Average Broker Recommendation 1.36 (Strong Buy)

CDTX Stock Price Chart Interactive Chart >

Price chart for CDTX

CDTX Price/Volume Stats

Current price $1.56 52-week high $3.21
Prev. close $1.59 52-week low $1.46
Day low $1.55 Volume 703,602
Day high $1.63 Avg. volume 618,350
50-day MA $1.99 Dividend yield N/A
200-day MA $2.12 Market Cap 77.23M

Cidara Therapeutics, Inc. (CDTX) Company Bio


Cidara Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. The company was founded in 2012 and is based in San Diego, California.


CDTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CDTX Latest Social Stream


Loading social stream, please wait...

View Full CDTX Social Stream

Latest CDTX News From Around the Web

Below are the latest news stories about Cidara Therapeutics Inc that investors may wish to consider to help them evaluate CDTX as an investment opportunity.

Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the closing of its previously announced concurrent but separate underwritten public offerings of 17,064,511 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,225,805 shares of common stock, at a price to the public of $1.55 per share and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of $15.50 per share. The gross proceeds to Cidara from these offerings, before deducting underwriting discounts and commissions and estimated offering expenses,...

Intrado Digital Media | October 13, 2021

Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the closing of its previously announced concurrent but separate underwritten public offerings of 17,064,511 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,225,805 shares of common st

Yahoo | October 13, 2021

Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate underwritten public offerings of 14,838,706 shares of its common stock at a price to the public of $1.55 per share and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of $15.50 per sh

Yahoo | October 8, 2021

Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it has commenced concurrent but separate underwritten public offerings of its common stock and its Series X Convertible Preferred Stock. With respect to the common stock offering, Cidara also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price. The closing of each proposed offering is not contingent upon the closing of the other. The offerings are subject to market conditions, and there can be no assurance as to whether or when either or both of the offerings will be c...

Intrado Digital Media | October 7, 2021

Should I Buy Cidara Therapeutics Inc (CDTX)?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 873 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | October 4, 2021

Read More 'CDTX' Stories Here

CDTX Price Returns

1-mo -30.36%
3-mo 1.96%
6-mo -30.04%
1-year -51.10%
3-year -58.95%
5-year -84.52%
YTD -22.00%
2020 -47.92%
2019 63.40%
2018 -65.44%
2017 -34.62%
2016 -39.39%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.8462 seconds.